| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-200211150-00001 |
| P698 | PubMed publication ID | 12451255 |
| P2093 | author name string | Satoshi Teraoka | |
| Tokihiko Sawada | |||
| Shohei Fuchinoue | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1207-1210 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis | |
| P478 | volume | 74 |
| Q35008036 | A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation |
| Q36162536 | A new concept of accommodation in ABO-incompatible kidney transplantation |
| Q37803412 | ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? |
| Q46702772 | ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment |
| Q28236829 | ABO incompatible renal transplants: Good or bad? |
| Q84820579 | ABO-incompatible kidney transplantation |
| Q41845634 | Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience |
| Q38267202 | An update on ABO-incompatible kidney transplantation |
| Q81566308 | Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q92112007 | Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients |
| Q42929012 | B-cell depletion improves islet allograft survival with anti-CD45RB. |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q40741639 | Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation |
| Q46452707 | Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofet |
| Q36171175 | Current progress in ABO-incompatible kidney transplantation |
| Q35554487 | Diagnosis and treatment of antibody-mediated kidney allograft rejection |
| Q36577151 | Drug insight: rituximab in renal disease and transplantation |
| Q44812532 | Early steroid withdrawal protocol using basiliximab in kidney transplantation |
| Q42169672 | Efficacy of basiliximab induction therapy in ABO-incompatible kidney transplantation: a rapid steroid withdrawal protocol |
| Q50542389 | Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation. |
| Q41310084 | Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation |
| Q80275366 | Experience with laparoscopic splenectomy for ABO-incompatible living renal transplantation without plasmapheresis |
| Q95645751 | Favorable Short-Term Outcome of Living Donor Kidney Transplantations in Flow Cytometry Crossmatch Positive Cases by Pretransplant Splenectomy: A Case Report |
| Q33334832 | Identification and characterization of peptide mimics of blood group A antigen |
| Q40538415 | Immunization by blood-type antigen in human immunoglobulin products before ABO-incompatible kidney transplantation |
| Q36586891 | Immunosuppressive preconditioning or induction regimens : evidence to date |
| Q38144106 | Impact of donor-specific antibodies in reconstructive transplantation |
| Q43660500 | Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. |
| Q104569586 | Impact of rituximab on the T-cell flow cytometric crossmatch |
| Q36967217 | Induction therapy in pediatric renal transplant recipients: an overview |
| Q36936436 | Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients |
| Q35953320 | Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation |
| Q51787282 | Initial experience with ABO-incompatible live donor renal transplantation. |
| Q87233834 | Interference of therapeutic antibodies used in desensitization protocols on lymphocytotoxicity crossmatch results |
| Q37305391 | Japan's experience with living-donor kidney transplantation across ABO barriers |
| Q35861272 | Low dose of mycophenolate mofetil is enough in desensitized kidney transplantation using rituximab |
| Q44935485 | Management of an ABO-incompatible lung transplant |
| Q36478827 | Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. |
| Q38376322 | Outcome of ABO-Incompatible Living Donor Renal Transplantations: A Single-Center Experience From Eastern India |
| Q55036659 | Overcoming a positive crossmatch in living-donor kidney transplantation. |
| Q53626859 | Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. |
| Q44989312 | Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy |
| Q47608382 | Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation |
| Q51809813 | Present status of ABO-incompatible kidney transplantation in Japan. |
| Q47712178 | Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation |
| Q46369129 | Results of kidney transplantation from ABO-incompatible living donors in a single institution |
| Q46369189 | Rituximab in highly sensitized kidney transplant recipients |
| Q27026434 | Rituximab in renal transplantation |
| Q44497155 | Splenic radiation and double-filtration plasmapheresis in crossmatch-positive live renal transplantation |
| Q37078119 | Successful renal transplantation with desensitization in highly sensitized patients: a single center experience |
| Q44222425 | Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation |
| Q35779272 | The clinical application of monoclonal antibody therapies in renal transplantation |
| Q34106158 | The generation and maintenance of serum alloantibody. |
| Q36054757 | The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients |
| Q46510240 | The use of 90yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics? |
| Q36772871 | The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection |
| Q38955520 | Therapeutic Apheresis in Hematologic, Autoimmune and Dermatologic Diseases With Immunologic Origin |
| Q39025553 | Therapeutic Apheresis in Immunologic Renal and Neurological Diseases |
Search more.